Key result
Dual anti-platelet therapy achieved higher percentage inhibition of platelet aggregation (65.14%) than monotherapy (48.89%), with prasugrel proving more effective than clopidogrel.
Why the study?
How do different oral anti-platelet regimens (single, dual, triple) affect the percentage inhibition of platelet aggregation in patients with coronary heart disease?
Observational (n=215)
No
How do different oral anti-platelet regimens (single, dual, triple) affect the percentage inhibition of platelet aggregation in patients with coronary heart disease?
Absolute Event Rate: 65.14% vs 48.89%
p-value: p=<0.001
Dual anti-platelet therapy, particularly with prasugrel, achieved the highest percentage inhibition of platelet aggregation compared to single or triple therapy in coronary heart disease patients.
No takes yet. Share an insight, caveat, or question.
DAPT with prasugrel linked to superior platelet inhibition in CHD; leaves open effects on clinical outcomes.
P. V. Kishan (2013) conducted an observational in Coronary Heart Disease (n=215). Dual anti-platelet therapy vs. Monotherapy was evaluated on Percentage Inhibition of Platelet Aggregation (% IPA) (p=<0.001). Dual anti-platelet therapy achieved higher percentage inhibition of platelet aggregation (65.14%) than monotherapy (48.89%), with prasugrel proving more effective than clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: